December 23, 2025

Task force touts greener endoscopy units

The authors argue that sustainability begins with appropriateness.

Conexiant

December 22, 2025

AGA strengthens payor ties to ease admin burden

“We view this as an opportunity to work together to alleviate some of these burdens, and I will say that hearing the perspective from payors has been very eye-opening.”

Conexiant

December 18, 2025

Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer

The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining...

The ASCO Post

December 18, 2025

FDA Approves Durvalumab With FLOT for Resectable Gastric/GEJ Adenocarcinoma

On November 25, 2025, the U.S. Food and Drug Administration (FDA) approved durvalumab (Imfinzi) in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuv...

The ASCO Post

December 17, 2025

What Your Microbiome Says About Your Heart

Metagenome-assembled genomes reveal species and pathways tied to coronary artery disease risk

The Pathologist

December 12, 2025

Parkinson's Aggravated by Nanoplastics Exposure

Mouse study suggests environmental nanoplastics may exacerbate Parkinson's disease through metabolic dysregulation in the gut, brain, and liver

The Pathologist

December 11, 2025

Will Spatial Genomics Help Identify Barrett’s Esophagus Patients at High Risk of Esophageal Cancer?

A Keck Medicine of USC expert explains how next-generation genetic analysis could help stratify patients’ cancer risk — and guide treatment decisions.

Keck Medicine of USC

December 11, 2025

GLP-1 drugs pose no cancer risk, review finds

A large systematic review and meta-analysis was limited by a median follow-up of 70 weeks.

Conexiant

December 11, 2025

Rebuilding Confidence in UK Pharma Manufacturing

The UK’s pharma manufacturing base still has potential, but only if companies modernize operations, boost efficiency, and show global investors that the UK can compete on cost and capability.

The Medicine Maker